06
Jun
Jun
Sufferers with early relapsed or refractory giant B-cell lymphoma had considerably improved general survival when handled with the chimeric antigen receptor (CAR) T cell remedy axicabtagene ciloleucel (axi-cel) when in comparison with the present standard-of-care chemoimmunotherapy, in line with outcomes of the Part III ZUMA-7 trial reported by researchers from The College of Texas MD […]